Iq-ai Ltd Regulatory News (IQAI)

IQ-AI Ltd

("IQ-AI" or the "Company")

New Development Aims to Detect Tumor Cell Infiltration

On the 19th June, the IQ-AI Board announced it was exploring a number of new initiatives and are looking at the wider application of IB technology and products. "IB CAD" is the first of such new developments.

IQ-AI Limited (LON:IQAI) and its subsidiary Imaging Biometrics, LLC (IB) has commenced the development of a cancer imaging technology, "IB CAD", that will detect cancer cells before they are visible on standard imaging. 

By combining multi-parameter magnetic resonance (MR) data and leveraging artificial intelligence (AI) algorithms, IB CAD will provide a structured way in which infiltrating tumor cells can be identified. In effect, IB CAD will have the potential to detect and identify sites of infiltrating tumor growth not visible with current imaging methods. IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.

Most brain tumor patients will undergo surgical resection with post-surgical therapy. The survival rates for these patients improve when more of the original tumor can be removed during surgery. For this reason, Neurosurgeons will usually remove neighboring tissue or "margins" that may otherwise appear healthy using current imaging techniques. In cases where the tumor has infiltrated eloquent cortex (areas of the brain that impact basic human functions such as speech, vision, motor skills or cognitive abilities), the removal of safe margins may be limited. In those cases, residual tumor remains and may not receive proper treatment until it grows large enough to be detected with current imaging. While advancements in radiotherapy treatment systems have surpassed the primitative imaging methods currently used to target tumor, these sophisticated advancements can only be realised when the target locations are known.

Approximately 50% of all cancer patients receive some sort of radiotherapy per the US National Cancer Institute, and the global radiotherapy market is expected to exceed $7 billion by 2023. This growth, however, is restricted by the inability to visualise areas of tumor1. The development of IB CAD, scheduled to take 18 months, will help lift this restriction. It is being designed for broad distribution and accessibility as well as for integration into radiotherapy planning systems.

Trevor Brown, IQ-AI CEO commented "This is a major new development. IB CAD will signify a paradigm shift in brain tumor management  and has the potential to enhance IB's leadership position in brain tumor imaging. A number of new ideas and projects are under preparation by the IB team and I will be communicating in detail on these over coming weeks"

Ref 1: Allied Market Research 

The Directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information, please contact:

ABOUT Imaging Biometrics™, LLC

Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.